Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both delivered strong quarters, but they tell very different dividend stories.

J&J is a Dividend King with 64 consecutive years of raises and a 2.02% yield. AbbVie pays a fatter 2.78%, funded by a narrower biopharma engine that carries more single-product risk.

Two Portfolios, Two Very Different Risk Shapes

J&J’s Q2 earnings report was broad. Worldwide sales hit $25.3 billion, with Innovative Medicine growing 6.8% and TREMFYA crossing $2 billion in a single quarter for the first time, up 71%. DARZALEX pushed past $4 billion. New launches ICOTYDE and INLEXZO are gaining share fast, which matters because STELARA is still bleeding to biosimilars.

AbbVie’s quarter was tighter but punchier. Revenue reached nearly $17 billion, up 10.2%, with Skyrizi at $5.5 billion (up 24%) and Rinvoq above $2.5 billion. Humira, meanwhile, fell 36.1% to $706 million. The math still works, but the concentration in immunology is real.

A Dividend King vs. an M&A Aggressor

J&J CEO Joaquin Duato called the company “one of the most compelling and transparent growth stories in healthcare today,” and he pointed to 28 products and platforms each doing more than $1 billion. That is the diversification safety net income investors pay up for.

CFO Joe Wolk was blunt about capital priorities: “We also remain committed to returning capital directly to shareholders, primarily through our dividend.” Free cash flow is tracking to roughly $21 billion for the year.

AbbVie is playing offense. Management just announced the $10.9 billion Apogee Therapeutics deal, adding long-acting biologics for atopic dermatitis and respiratory disease. That deal alone knocks $0.14 off 2026 EPS.

CEO Robert Michael framed it as fuel for the 2030s: “AbbVie’s long-term outlook remains very strong.” The tradeoff is a book value that is already negative and a trailing P/E near 69, distorted by acquisition accounting.

The Next Test Is Post-Humira Durability

For J&J, I want to see whether ICOTYDE and INLEXZO keep outrunning competitor launches, and whether the mid-2027 DePuy Synthes separation actually lifts the multiple. Cardiovascular growth of 3.1% was soft, so Abiomed needs to stabilize.

For AbbVie, the Skyrizi subcutaneous Crohn’s decision this fall and Tevapadon’s Parkinson’s launch will matter more than the headline yield. Skyrizi’s composition-of-matter patent runs to 2033, so the cliff conversation is not urgent, but it is on the calendar.

Why I Lean Toward J&J for Income, ABBV for Total Return

If I want a dividend I can forget about, J&J wins. The 64-year streak, AAA-rated balance sheet, and diversified cash flows do the heavy lifting. The yield is modest, but so is the risk of a cut. Shares are also up 27.92% year to date, so the safety trade has already paid.

If I want more yield and I am willing to underwrite Skyrizi, Rinvoq, and the Apogee bet, AbbVie is the more interesting name. The 11.09% YTD gain lags J&J, but a successful post-Humira transition could re-rate the stock. I would own it because I believe in the immunology franchise, not for the dividend alone. That is a different bet than J&J, and readers should treat it that way.

Contact [email protected] for any questions or corrections.